IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates

Bulletin Express06-03

IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong District, Shanghai.

Key matters for shareholder approval:

1. 2025 Operating Review • The Board’s 2025 work report will be presented for consideration. • The audited accountant’s report for the financial year ended 31 December 2025 is up for approval.

2. Profit Distribution • A 2025 profit distribution plan will be submitted to shareholders. Specific payout details were not disclosed in the proxy.

3. Auditor Continuation • Re-appointment of the Company’s auditor for the 2026 financial year, with the Board authorised to determine remuneration.

4. Articles of Association Amendment (Special Resolution) • Proposed revisions to the Company’s Articles of Association to be voted on by shareholders.

5. Capital Management Mandates (Special Resolutions) • A general mandate empowering the Board to issue additional shares. • A separate mandate authorising the Board to repurchase H shares.

Procedural Notes • Shareholders may appoint the AGM chairman or another proxy to vote. • Proxy forms and any supporting authorisations must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 24 June 2026. • Identity documentation is required for in-person attendance.

The resolutions, if approved, will guide IMPACT Therapeutics’ governance, capital management and financial reporting framework for the 2026 fiscal year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123127100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123127100","market":"us","top_or_hot":-1,"title":"IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates","media":"Bulletin Express","content":"<p>IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong District, Shanghai.</p>\n<p>Key matters for shareholder approval:</p>\n<p>1. 2025 Operating Review  \n   • The Board’s 2025 work report will be presented for consideration.  \n   • The audited accountant’s report for the financial year ended 31 December 2025 is up for approval.</p>\n<p>2. Profit Distribution  \n   • A 2025 profit distribution plan will be submitted to shareholders. Specific payout details were not disclosed in the proxy.</p>\n<p>3. Auditor Continuation  \n   • Re-appointment of the Company’s auditor for the 2026 financial year, with the Board authorised to determine remuneration.</p>\n<p>4. Articles of Association Amendment (Special Resolution)  \n   • Proposed revisions to the Company’s Articles of Association to be voted on by shareholders.</p>\n<p>5. Capital Management Mandates (Special Resolutions)  \n   • A general mandate empowering the Board to issue additional shares.  \n   • A separate mandate authorising the Board to repurchase H shares.</p>\n<p>Procedural Notes  \n• Shareholders may appoint the AGM chairman or another proxy to vote.  \n• Proxy forms and any supporting authorisations must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 24 June 2026.  \n• Identity documentation is required for in-person attendance.</p>\n<p>The resolutions, if approved, will guide IMPACT Therapeutics’ governance, capital management and financial reporting framework for the 2026 fiscal year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-03 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong District, Shanghai.</p>\n<p>Key matters for shareholder approval:</p>\n<p>1. 2025 Operating Review  \n   • The Board’s 2025 work report will be presented for consideration.  \n   • The audited accountant’s report for the financial year ended 31 December 2025 is up for approval.</p>\n<p>2. Profit Distribution  \n   • A 2025 profit distribution plan will be submitted to shareholders. Specific payout details were not disclosed in the proxy.</p>\n<p>3. Auditor Continuation  \n   • Re-appointment of the Company’s auditor for the 2026 financial year, with the Board authorised to determine remuneration.</p>\n<p>4. Articles of Association Amendment (Special Resolution)  \n   • Proposed revisions to the Company’s Articles of Association to be voted on by shareholders.</p>\n<p>5. Capital Management Mandates (Special Resolutions)  \n   • A general mandate empowering the Board to issue additional shares.  \n   • A separate mandate authorising the Board to repurchase H shares.</p>\n<p>Procedural Notes  \n• Shareholders may appoint the AGM chairman or another proxy to vote.  \n• Proxy forms and any supporting authorisations must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 24 June 2026.  \n• Identity documentation is required for in-person attendance.</p>\n<p>The resolutions, if approved, will guide IMPACT Therapeutics’ governance, capital management and financial reporting framework for the 2026 fiscal year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1123127100","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123127100","pubTimestamp":1780484712,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"IMPACT Therapeutics定于2026年6月25日召开年度股东大会；股东将就2025年业绩、审计师续聘和双重授权进行投票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong District, Shanghai.\nKey matters for shareholder approval:\n1. 2025 Operating Review  \n   • The Board’s 2025 work report will be presented for consideration.  \n   • The audited accountant’s report for the financial year ended 31 December 2025 is up for approval.\n2. Profit Distribution  \n   • A 2025 profit distribution plan will be submitted to shareholders. Specific payout details were not disclosed in the proxy.\n3. Auditor Continuation  \n   • Re-appointment of the Company’s auditor for the 2026 financial year, with the Board authorised to determine remuneration.\n4. Articles of Association Amendment (Special Resolution)  \n   • Proposed revisions to the Company’s Articles of Association to be voted on by shareholders.\n5. Capital Management Mandates (Special Resolutions)  \n   • A general mandate empowering the Board to issue additional shares.  \n   • A separate mandate authorising the Board to repurchase H shares.\nProcedural Notes  \n• Shareholders may appoint the AGM chairman or another proxy to vote.  \n• Proxy forms and any supporting authorisations must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 24 June 2026.  \n• Identity documentation is required for in-person attendance.\nThe resolutions, if approved, will guide IMPACT Therapeutics’ governance, capital management and financial reporting framework for the 2026 fiscal year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123127100","isCrawlerRequest":true}